![James Dentzer](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
James Dentzer
Directeur Général chez CURIS, INC.
Fortune : 18 617 $ au 31/12/2024
Profil
James E.
Dentzer's current job(s) include being the President, Chief Executive Officer & Director at Curis, Inc. since 2019, and an Independent Director at Imunon, Inc. since 2022.
Mr. Dentzer's former job(s) include being the Chief Financial Officer-DuPont Flooring Systems at EIDP, Inc., Controller at Biogen, Inc. from 2003 to 2006, Chief Financial Officer at Amicus Therapeutics, Inc. from 2006 to 2009, Chief Financial Officer at Dicerna Pharmaceuticals, Inc. from 2013 to 2015, and Chief Financial Officer at Valeritas, Inc. from 2010 to 2013.
Mr. Dentzer's education history includes an undergraduate degree from Boston College and an MBA from The University of Chicago Booth School of Business.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CURIS, INC.
0,07% | 21/05/2024 | 6 084 ( 0,07% ) | 18 617 $ | 31/12/2024 |
IMUNON, INC.
-.--% | 06/09/2024 | 0 ( -.--% ) | - $ | 31/12/2024 |
Dernières actualités sur James Dentzer
Postes actifs de James Dentzer
| Sociétés | Poste | Début |
|---|---|---|
| CURIS, INC. | Directeur Général | 24/09/2018 |
| IMUNON, INC. | Directeur/Membre du Conseil | 03/09/2022 |
Anciens postes connus de James Dentzer
| Sociétés | Poste | Fin |
|---|---|---|
| DICERNA PHARMACEUTICALS, INC. | Directeur Financier/CFO | 15/12/2015 |
| VALERITAS INC | Directeur Financier/CFO | 01/12/2013 |
| AMICUS THERAPEUTICS, INC. | Directeur Financier/CFO | 29/10/2009 |
| BIOGEN INC. | Comptroller/Controller/Auditor | - |
| E I DU PONT DE NEMOURS AND CO | Corporate Officer/Principal | - |
Formation de James Dentzer
| Boston College | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| AMICUS THERAPEUTICS, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| CURIS, INC. | Health Technology |
| IMUNON, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
EIDP, Inc.
 EIDP, Inc. Chemicals: AgriculturalProcess Industries EIDP, Inc. engages in the provision of science-based products and services. It operates through the Seed and Crop Protection segments. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms around the world. The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The company was founded by Eleuthere Irenee du Pont in 1802 and is headquartered in Indianapolis, IN. | Process Industries |
Valeritas, Inc.
 Valeritas, Inc. Medical SpecialtiesHealth Technology Valeritas, Inc. engages in the development and commercialization of drug delivery solutions for the treatment of diabetes. Its product, V-Go wearable insulin delivery device, which enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery by using one type of insulin at a continuous preset basal rate over a 24-hour period and provides on-demand bolus dosing for meals and snacks. The company was founded on August 2, 2006 and is headquartered in Bridgewater, NJ. | Health Technology |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. | Health Technology |
